B cells in multiple sclerosis

Autoimmunity

Volumn 50, Issue 1, 2017, Pages 57-60

  Wekerle, Hartmut ^a  

^a MPI Neurobiology   (Germany)

Author keywords

autoimmunity; B cell; central nervous system; experimental autoimmune encephalomyelitis; Multiple sclerosis

Indexed keywords

AUTOANTIGEN; OLIGOCLONAL BAND; AUTOANTIBODY; BIOLOGICAL MARKER;

AUTOIMMUNITY; B LYMPHOCYTE; CELL THERAPY; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HUMAN; MULTIPLE SCLEROSIS; NONHUMAN; REVIEW; ANIMAL; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; TUMOR MICROENVIRONMENT;

ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNITY; B-LYMPHOCYTES; BIOMARKERS; CELLULAR MICROENVIRONMENT; CENTRAL NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; MULTIPLE SCLEROSIS; OLIGOCLONAL BANDS;

EID: 85011840984     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916934.2017.1281914     Document Type: Review

References (32)

1. Esiri, M. M., 1980. Multiple sclerosis:a quantitative and qualitative study of immunoglobulin-containing cells in the central nervous system. Neuropathol. Appl. Neurobiol. 6:9–21
2. Serafini, B., B., Rosicarelli, R., Magliozzi, et al. 2004. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 14:164–144
3. Lucchinetti, C. F., B. F. G., Popescu, R. F., Bunyan, et al. 2011. Inflammatory cortical demyelination in early multiple sclerosis. N. Engl. J. Med. 365:2188–2197
4. Obermeier, B., R. Mentele, J., Malotka, et al. 2008. Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. Nat. Med. 14:688–693
5. Brändle, S., B., Obermeier, M., Senel, et al. 2016. Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins. Proc. Natl. Acad. Sci. USA. 113:7864–7869
6. Brennan, K. M., F., Galban-Horcajo, S., Rinaldi, et al. 2011. Lipid arrays identify myelin-derived lipids and lipid complexes as prominent targets for oligoclonal band antibodies in multiple sclerosis. J. Neuroimmunol. 238:87–95
7. Walsh, M. J., and W. W., Tourtellotte. 1986. Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis. J. Exp. Med. 163:41–53
8. Neumann, H., and H., Wekerle. 1998. Neuronal control of the immune response in the central nervous system:linking brain immunity to neurodegeneration. J. Neuropathol. Exp. Neurol. 57:1–9
9. Krumbholz, M., D., Theil, T., Derfuss, et al. 2005. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J. Exp. Med. 201:195–200
10. von Büdingen, H. C., T. C., Kuo, M., Sirota, et al. 2012. B cell exchange across the blood-brain barrier in multiple sclerosis. J. Clin. Invest. 122:4533–4543
11. Lucchinetti, C. F., W., Brück, J., Parisi, et al. 2000. Heterogeneity of multiple sclerosis lesions:implications for the pathogenesis of demyelination. Ann. Neurol. 47:707–717
12. Keegan, M., F., König, R., McClelland, et al. 2005. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet. 366:579–582
13. Magliozzi, R., O., Howell, A., Vora, et al. 2007. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 130:1089–1104
14. Hauser, S. L., E., Waubant, D. L., Arnold, et al. 2008. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358:676–688
15. Srivastava, R., M., Aslam, S. R., Kalluri, et al. 2012. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N. Engl. J. Med. 367:115–123
16. Pröbstel, A. K., J., Kuhle, A. C., Lecourt, et al. 2016. Multiple sclerosis and antibodies against KIR4.1. N. Engl. J. Med. 374:1496–1498
17. Derfuss, T., C., Linington, R., Hohlfeld, and E., Meinl. 2010. Axo-glial antigens as targets in multiple sclerosis:implications for axonal and grey matter injury. J. Mol. Med. 88:753–761
18. Bar-Or, A., R. Q., Hintzen, R. C., Dale, et al. 2016. Immunopathophysiology of pediatric CNS inflammatory demyelinating diseases. Neurology. 87:S12–S19
19. Probstel, A. K., G., Rudolf, K., Dornmair, et al. 2015. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J. Neuroinflamm. 12:46
20. Mayer, M. C., C., Breithaupt, M., Reindl, et al. 2013. Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory CNS diseases. J. Immunol. 191:3594–3604
21. Krumbholz, M., T., Derfuss, R., Hohlfeld, and E., Meinl. 2012. B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat. Rev. Neurol. 8:613–623
22. Krishnamoorthy, G., H., Lassmann, H., Wekerle, and A., Holz. 2006. Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. J. Clin. Invest. 116:2385–2392
23. Krishnamoorthy, G., A., Saxena, L. T., Mars, et al. 2009. Myelin specific T cells also recognize neuronal autoantigen in a transgenic mouse model of multiple sclerosis. Nature Med. 15:626–632
24. Pöllinger, B., G., Krishnamoorthy, K., Berer, et al. 2009. Spontaneous relapsing-remitting EAE in the SJL/J mouse:MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells. J. Exp. Med. 206:1303–1316
25. Berer, K., M., Mues, M., Koutrolos, et al. 2011. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature. 479:538–541
26. Wekerle, H., 2015. Nature plus nurture:the triggering of multiple sclerosis. Swiss Med. Wkly. 145:w14189
27. Gilhus, N. E., and J. J., Verschuuren. 2015. Myasthenia gravis:subgroup classification and therapeutic strategies. Lancet Neurol. 14:1023–1036
28. Edwards, J. C. W., and G., Cambridge. 2006. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat. Rev. Immunol. 6:394–403
29. Salzer, J., R., Svenningsson, P., Alping, et al. 2016. Rituximab in multiple sclerosis:a retrospective observational study on safety and efficacy. Neurology. 87:2074–2081
30. Hauser, S. L., 2015. The Charcot Lecture–beating MS:a story of B cells, with twists and turns. Mult. Scler. 21:8–21
31. Kappos, L., H. P., Hartung, M. S., Freedman, et al. 2014. Atacicept in multiple sclerosis (ATAMS):a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurol. 13:353–363
32. Vincent, F. B., E. F., Morand, P., Schneider, and F., Mackay. 2014. The BAFF/APRIL system in SLE pathogenesis. Nat. Rev. Rheumatol. 10:365–373